- Home
- USIO vs IPSC Comparison
USIO vs IPSC Comparison
Compare USIO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- IPSC
- Stock Information
- Founded
- USIO 1998
- IPSC 2019
- Country
- USIO United States
- IPSC United States
- Employees
- USIO N/A
- IPSC N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- USIO Finance
- IPSC Health Care
- Exchange
- USIO Nasdaq
- IPSC Nasdaq
- Market Cap
- USIO 37.6M
- IPSC 43.2M
- IPO Year
- USIO N/A
- IPSC 2021
- Fundamental
- Price
- USIO N/A
- IPSC $0.58
- Analyst Decision
- USIO Strong Buy
- IPSC Strong Buy
- Analyst Count
- USIO 1
- IPSC 5
- Target Price
- USIO $4.00
- IPSC $3.33
- AVG Volume (30 Days)
- USIO 99.4K
- IPSC 535.0K
- Earning Date
- USIO 11-05-2025
- IPSC 11-04-2025
- Dividend Yield
- USIO N/A
- IPSC N/A
- EPS Growth
- USIO N/A
- IPSC N/A
- EPS
- USIO 0.11
- IPSC N/A
- Revenue
- USIO $83,851,606.00
- IPSC $114,128,000.00
- Revenue This Year
- USIO $8.71
- IPSC $1,589.94
- Revenue Next Year
- USIO $12.48
- IPSC N/A
- P/E Ratio
- USIO $13.46
- IPSC N/A
- Revenue Growth
- USIO 2.05
- IPSC 5491.77
- 52 Week Low
- USIO $1.24
- IPSC $0.34
- 52 Week High
- USIO $2.92
- IPSC $1.83
- Technical
- Relative Strength Index (RSI)
- USIO 46.46
- IPSC 69.35
- Support Level
- USIO $1.39
- IPSC $0.48
- Resistance Level
- USIO $1.49
- IPSC $0.51
- Average True Range (ATR)
- USIO 0.06
- IPSC 0.03
- MACD
- USIO 0.01
- IPSC 0.01
- Stochastic Oscillator
- USIO 45.11
- IPSC 94.98
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.